Novo Nordisk adds four registrations: new molecule trial, CagriSema switch study, real-world data

Novo Nordisk A/S added several new trial registrations and kept its two Phase 3 zenagamtide studies recruiting as of September 30, 2026.

• AMAZE 9 (NCT07720271), a Phase 3 trial of once-daily oral zenagamtide tablets in participants with overweight or obesity, remains recruiting. Its primary outcome is relative change in body weight, measured as percentage change in body weight, from baseline at week 0 to week 76.¹ The study plans to enroll 950 participants.¹
• AMAZE 7 (NCT07668414), a Phase 3 trial comparing once-weekly subcutaneous zenagamtide to once-weekly subcutaneous semaglutide in obesity, remains recruiting. Its primary outcome is relative change in body weight, measured as percentage change, from week 0 to week 84.² The study covers overweight and obesity.²
• A new Phase 1 first-in-human study (NCT07797855) is recruiting to test NNC0705-0002. The trial assesses safety, tolerability, pharmacokinetics, target engagement, and absorption, metabolism and excretion of NNC0705-0002 after single and multiple oral doses in healthy adults.³ The medicine is being developed for conditions where inflammation may contribute to heart and metabolic health problems.³ It plans to enroll 112 participants.³
• A new Phase 3 trial (NCT07817251) is recruiting to study switching patients with type 2 diabetes from semaglutide to CagriSema. The study examines safety and tolerability of three switch regimens from semaglutide 1.0 mg and 2.0 mg to co-administered cagrilintide and semaglutide.⁴ Its primary outcome is the number of treatment emergent adverse events from baseline to week 16.⁴ The trial lists 40 sites in the United States.⁴
• A new Phase 1 trial (NCT07845578) is not yet recruiting to examine gastric emptying with high-dose subcutaneous semaglutide in obesity. The study will determine the effect of semaglutide on gastric emptying in people with obesity.⁵ It plans to enroll 60 participants.⁵
• An observational study (NCT07781371), SCALA-TK-CM, is active but not recruiting. It aims to determine the prevalence and overlap of major cardiometabolic diseases using anonymized electronic health record data spanning January 2022 to December 2025.⁶ The study plans to enroll 100,000 participants.⁶
• A completed observational study (NCT07850765), sEMa-LIFE, reports on patient and physician experience with Wegovy (semaglutide) across six emerging markets. It included patients who had been diagnosed with overweight or obesity and initiated on Wegovy at least 16 weeks prior to a disease specific programme survey.⁷ Its primary outcomes include change in Food Noise Questionnaire score, assessed retrospectively before Wegovy initiation and at data capture.⁷